Researchers Receive Grants from NCCN Oncology Research Program Funded through Boehringer Ingelheim
Saved in:
| Title: | Researchers Receive Grants from NCCN Oncology Research Program Funded through Boehringer Ingelheim |
|---|---|
| Authors: | National Comprehensive Cancer Network |
| Source: | Business Wire (English). 09/04/2012. |
| Abstract: | The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded five research grants to investigators following NCCN ORP Scientific Review Committee analysis of proposals submitted in response to the NCCN Afatinib Request for Proposals. These grants were made possible through a $2-million research grant from Boehringer Ingelheim Pharmaceuticals, Inc. to scientifically evaluate and define the clinical effectiveness of afatinib (BIBW 2992) in solid tumors, including breast, non-small cell lung (NSCLC), and head and neck cancers. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded five research grants to investigators following NCCN ORP Scientific Review Committee analysis of proposals submitted in response to the NCCN Afatinib Request for Proposals. These grants were made possible through a $2-million research grant from Boehringer Ingelheim Pharmaceuticals, Inc. to scientifically evaluate and define the clinical effectiveness of afatinib (BIBW 2992) in solid tumors, including breast, non-small cell lung (NSCLC), and head and neck cancers. [ABSTRACT FROM PUBLISHER] |
|---|
